Alzheimer’s Disease And Dementia

Biomarkers of Alzheimer Disease Observed in Down Syndrome

Biomarkers of Alzheimer Disease Observed in Down Syndrome

By

Neurological and neuropsychological examinations were performed to assess intellectual disabilities, and biological assays were performed on collected CSF and plasma.

Tau PET Is a Reliable Biomarker for Cognitive Decline in Older Adults

Tau PET Is a Reliable Biomarker for Cognitive Decline in Older Adults

By

Investigators evaluated cognition with measures reflecting executive function, episodic memory, semantic fluency, and processing speed on an annual basis.

Confabulations Linked to Impaired Mental Time Travel in Alzheimer Disease

Confabulations Linked to Impaired Mental Time Travel in Alzheimer Disease

By

The findings suggest that confabulations by patients with AD are related to an impaired ability to mentally go back in time to retrieve the context in which the confabulated memories were encoded.

Link Between Lower Cognitive Ability in Young Adults and Risk for Dementia

Link Between Lower Cognitive Ability in Young Adults and Risk for Dementia

By

Lower cognitive ability total and verbal ability scores were predictive of greater risk for early-onset dementia.

Promising Improvements in Mild Cognitive Impairment With Investigational NA-831

Promising Improvements in Mild Cognitive Impairment With Investigational NA-831

By

Researchers from NeuroActiva, Inc. presented results of their randomized, double-blind, placebo-controlled phase 2A clinical trial of NA-831.

Tramiprosate Associated With High Response, Favorable Safety in APOE ε4 Homozygotes With Mild Alzheimer's

Tramiprosate Associated With High Response, Favorable Safety in APOE ε4 Homozygotes With Mild Alzheimer's

By

Researchers assessed individual patient responses as well as overall response rates to oral tramiprosate and the effect of response on clinical outcomes.

Twice-Daily Oxaloacetate Activates Brain Bioenergetic Metabolism in Alzheimer Disease

Twice-Daily Oxaloacetate Activates Brain Bioenergetic Metabolism in Alzheimer Disease

By

The study assessed the pharmacokinetics and pharmacodynamics of 2 doses of oxaloacetate in patients with Alzheimer disease.

New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's

New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's

By

Initial data from Study 201, as announced in December 2017, showed BAN2401 did not meet the primary endpoint.

Investigating the Effects of Z-Drugs in Dementia Patients With Sleep Disturbances

Investigating the Effects of Z-Drugs in Dementia Patients With Sleep Disturbances

By

Existing data from the the UK Clinical Practice Research Datalink (CPRD) and 3 clinical studies of PwD were used to evaluate the association between Z-drug administration and the incidence of adverse events.

Metformin Associated With Increased Dementia Risk in African Americans With Diabetes

Metformin Associated With Increased Dementia Risk in African Americans With Diabetes

By

Participants in this study were part of the Indianapolis-Ibadan Dementia Project that took place from 1992 to 2011 and were assessed for dementia every second or third year during follow-up.

Pimavanserin Confers Greater Improvements in Alzheimer Disease Psychosis vs Placebo

Pimavanserin Confers Greater Improvements in Alzheimer Disease Psychosis vs Placebo

By

Pimavanserin is currently approved in the United States for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Transdermal Buprenorphine Not Well Tolerated in Dementia

Transdermal Buprenorphine Not Well Tolerated in Dementia

By

The researchers conducted a 13-week study that included 162 individuals with advanced dementia and considerable depression residing in nursing homes in Norway.

Cannabinoid Shows Promise for Reducing Agitation, Aggression in Alzheimer Disease

Cannabinoid Shows Promise for Reducing Agitation, Aggression in Alzheimer Disease

By

Although treatment with nabilone significantly improved agitation, cognition, and nutrition, the authors cautioned that sedation should be closely monitored.

Sugary Drinks, Other Added Sugars May Up Risk for Alzheimer Disease

Sugary Drinks, Other Added Sugars May Up Risk for Alzheimer Disease

By

Drinking sugary beverages has been previously linked to markers of preclinical Alzheimer disease, but the risk associated with consuming added sugars is not established.

Intensive Blood Pressure Control Cuts Combined Mild Cognitive Impairment, Dementia Risk

Intensive Blood Pressure Control Cuts Combined Mild Cognitive Impairment, Dementia Risk

By

In the previous SPRINT study, researchers compared an intensive BP reduction strategy (target systolic BP <120 mmHg) vs standard BP reduction strategy (target systolic BP <140 mmHg).

Citicoline Plus Memantine Superior to Memantine Alone for Improving Cognition in Alzheimer's Dementia

Citicoline Plus Memantine Superior to Memantine Alone for Improving Cognition in Alzheimer's Dementia

By

Patients in the combination treatment arm experienced a greater increase in MMSE scores between baseline and at 6 months compared with those receiving memantine monotherapy.

Diclofenac Use Slows Cognitive Decline in Alzheimer Disease

Diclofenac Use Slows Cognitive Decline in Alzheimer Disease

By

Study results showed that most common NSAIDs, including aspirin, ibuprofen, naproxen, and celecoxib did not alter cognitive degeneration in patients with mild cognitive impairment or Alzheimer disease.

Eicosapentaenoic Acid Exerts Protective Effect on Alzheimer's Dementia Risk

Eicosapentaenoic Acid Exerts Protective Effect on Alzheimer's Dementia Risk

By

There was a significant relationship between plasma levels of eicosapentaenoic acid and Alzheimer disease dementia.

Pregnancy History Plays a Role in Alzheimer Disease Risk

Pregnancy History Plays a Role in Alzheimer Disease Risk

By

The researchers investigated whether the potential relationship between pregnancy and AD risk was linked to an immunologic mechanism.

Some Statins May Be Associated With Cognition, Memory Deficits

Some Statins May Be Associated With Cognition, Memory Deficits

By

Given the lack of differences seen via the NIS, the authors suggested that subjective questionnaires may not be a trustworthy method to assess possible statin-associated cognitive deficits.

Association Between Alcohol Consumption, Cognitive Function Revealed

Association Between Alcohol Consumption, Cognitive Function Revealed

By

Participants were drawn from the Health and Retirement Study, which provided multiple observations, genetic information, and previous alcohol use.

Donepezil Dose Titration Improves Tolerability in Alzheimer Disease

Donepezil Dose Titration Improves Tolerability in Alzheimer Disease

By

High-dose donepezil is currently indicated for patients with Alzheimer disease who have poor response to the lower dose.

Diabetes, Prediabetes Hasten Mental Decline in Older Adults

Diabetes, Prediabetes Hasten Mental Decline in Older Adults

By

Magnetic resonance imaging scans revealed smaller total brain tissue volume and a significant decrease in white matter volume in participants with prediabetes.

Hormone Replacement Therapy Associated With Reduced Dementia Risk in Postmenopausal Women

Hormone Replacement Therapy Associated With Reduced Dementia Risk in Postmenopausal Women

By

Individuals who underwent 2 to 5 years of hormone replacement therapy experienced the greatest risk reduction.

Novel PDE-9 Inhibitor Shows No Benefit for Prodromal, Mild Alzheimer Disease

Novel PDE-9 Inhibitor Shows No Benefit for Prodromal, Mild Alzheimer Disease

By

BI 409306 is a novel selective phosphodiesterase-9A inhibitor being examined for its safety, efficacy, and tolerability in patients with prodromal and mild Alzheimer disease.

Low-Dose Gantenerumab Shows Promise for Alzheimer Disease

Low-Dose Gantenerumab Shows Promise for Alzheimer Disease

By

In a previous study, SCarlet RoAD, gantenerumab had demonstrated a dose-dependent effect on CSF tau species.

Alzheimer's Age of Onset Exerts Significant Effect on Risk Factors for Mortality

Alzheimer's Age of Onset Exerts Significant Effect on Risk Factors for Mortality

By

Affected life expectancy was characterized for each patient using determinants such as sex, APOE genotype, solitary-living, duration of AD, age at onset, years of education, concomitant medications, activities of daily living, cognitive functioning, and rate of decline.

New Clinical Guideline for Evaluating Alzheimer's, Related Dementias

New Clinical Guideline for Evaluating Alzheimer's, Related Dementias

By

Currently, there are no US consensus on best clinical practice guidelines that incorporate multispecialty recommendations for evaluating cognitive impairment that are thought to be due to Alzheimer's disease and Related Dementias (ADRD) for use by physicians and nurse practitioners.

Aducanumab Beneficial in Cognitive, Functional Scores for Alzheimer Disease

Aducanumab Beneficial in Cognitive, Functional Scores for Alzheimer Disease

By

The analysis suggests a beneficial effect of aducanumab on functional and cognitive domain scores in adults with Alzheimer disease.

Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications

Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications

By

Funding needs to be more widely available to help implement these effective nonpharmacologic interventions.

Sign Up for Free e-newsletters



CME Focus